Seon’s first regulated medical device product targets Diabetic Retinopathy ('DR'), a disease of the light-sensitive membrane at the back of the eye, caused by diabetes. Around a third of all diabetics go on to develop DR which is one of the leading causes of blindness globally. Identified early, DR is eminently treatable. However, millions of people around the world living with diabetes have no access to routine eye screening. Consequently they are at risk of sight impairment and its devastating effects. DR is a large and growing problem, driven by the global diabetes epidemic. By 2045 it is estimated there will be some 780M diabetics around the world, representing 12% of the global adult population.
Seon's screening platform will enable the development of a range of screening products for other chronic diseases in addition to DR, for example, in cardiovascular, renal and neurological diseases.